Hung Trinh, Senior VP of Operations at Seneca Therapeutics, shared a post on LinkedIn:
“GSK pens $357M pact with French biotech for preclinical prostate cancer ADC
Fresh from a European cancer conference that was all about antibody-drug conjugates, GSK has turned to French biotech Syndivia for a preclinical prostate cancer prospect.
Syndivia’s ADC has already proven its effectiveness at shrinking tumors in preclinical studies ‘without causing a proportional increase in significant side effects, even at higher doses,’ GSK explained in an Oct. 27 release. The British pharma is betting the candidate can be targeted directly at tumors, for which there is ‘currently a gap in available therapies’ in the community practice setting for metastatic castration-resistant prostate cancer (mCRPC).
GSK is eligible to pay up to 268 million pounds sterling ($357 million) in a combination of upfront, development and commercial milestone payments, although the companies didn’t break down the financial details.
‘Prostate cancer represents a significant health burden and an emerging area of growth for GSK, where targeted therapies are urgently needed in metastatic castration-resistant settings. The addition of this ADC builds on GSK’s growing portfolio and strengths in tumour-targeted technologies, including GSK ’227, our B7-H3-targeting ADC,’ Hesham Abdullah, M.D., global head of oncology R&D at GSK, said in this morning’s release.”
More posts featuring Hung Trinh.